New drug aims to cure chronic hepatitis b in landmark trial

NCT ID NCT06829329

Ongoing Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This Phase 2 trial tests an experimental drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can clear the hepatitis B surface antigen and lower the virus to undetectable levels, potentially leading to a functional cure. Participants will receive AHB-137, standard antivirals, or a placebo, and be followed for safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-137 (an experimental drug)
What this could lead to: If successful, this could point toward a functional cure for chronic hepatitis B, where the virus is suppressed and treatment can be stopped.
What could go wrong: This is an early Phase 2 trial with only 105 participants. The drug may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

AusperBio Investigational Site

Guangzhou, Guangdong, China
AusperBio Investigational Site

Changzhou, Jiangsu, China
Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 401336, China
The Third People's Hospital of Zhenjiang

Zhenjiang, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.